More on serotonin syndrome associated with triptan monotherapy

New England Journal of Medicine

Volumn 359, Issue 8, 2008, Pages 870-871

  Evans, Randolph W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIPTAN DERIVATIVE;

FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MEDICAL INFORMATION; MONOTHERAPY; PRIORITY JOURNAL; SEROTONIN SYNDROME;

EID: 49949113673     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc086283     Document Type: Letter

References (5)

1. Soldin OP, Tonning JM. Serotonin syndrome associated with triptan monotherapy. N Engl J Med 2008;358:2185-6.
2. Food and Drug Administration. Information for healthcare professionals: selective serotonin reuptake inhibitors (SSRIs), selective serotonin- norepinephrine reuptake inhibitors (SNRIs), 5-hydroxytryptamine receptor agonists (triptans). July 19, 2006. (Accessed August 1, 2008, at http://www.fda.gov/cder/drug/InfoSheets/HCP/triptansHCP.htm.)
3. Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports. Medscape Gen Med 2007;9(3):48. (Accessed August 1, 2008, at http://www.medscape.com/viewarticle/ 561741.)
4. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 2007;47:266-9.
5. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005;28:205-14.